Status: Recruiting
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis
Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Keymed Biosciences Co.LtdUpdated: Nov 26, 2025Locations: 2
Eligibility criteria
Voluntary provision of written informed consent and ability to comply with proto... [+7]
Current or prior diagnosis of multiple myeloma. [+4]